Press Release

July 3, 2026 BSE Limited Code: 532321 P J Towers, Dalal Street, Mumbai-400001 National Stock Exchange of India Limited Code: Zyduslife Exchange Plaza, C/1, Block G, Bandra-Kurla Complex, Bandra (East), Mumbai-400051 Re.: Press Release Dear Sir / Madam, Please find enclosed a copy of press release dated July 3, 2026, titled “Zydus signs MoU with Apollo Hospitals to expand access to the Shield™ Multi-Cancer Detection test (MCD) in India”. The contents of the press release give full details. Please bring the aforesaid news to the notice of the members of the exchange and the investors’ at large. Yours faithfully, For, Zydus Lifesciences Limited Dhaval N. Soni Company Secretary and Compliance Officer Membership No. FCS7063 Encl.: As above Zydus signs MoU with Apollo Hospitals to expand access to the Shield™ Multi-Cancer Detection test (MCD) in India Ahmedabad, Chennai, 3 July 2026 Zydus Lifesciences Ltd. (Zydus), an innovation driven global lifesciences company and Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, have an exclusive agreement to make the Shield™ Multi-Cancer Detection (MCD) test available in India, for which Zydus has signed a Memorandum of Understanding (MoU) with Apollo Hospitals to offer the test in the territory. The Shield MCD test is a methylation-based blood test for the detection of multiple cancer types including bladder, colorectal, breast, prostate, oesophageal, gastric, liver, lung, ovarian and pancreas cancer in individuals aged 45 or older and who are at typical average risk for cancer. With just a blood draw, the test screens for 10 of the most common cancers, many of which have high mortality rates in India. The test has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA)*, recognising its potential to provide more effective screening for cancers than existing options. Speaking on this development, Dr. Prathap C. Reddy, Chairman, Apollo Hospitals Group, said, "At Apollo, we have long believed that the most effective healthcare is proactive healthcare. The future of medicine lies not only in treating disease, but in preventing it and detecting it at its earliest, most treatable stages. Cancer continues to be one of the greatest health challenges facing societies worldwide, and expanding access to timely, reliable screening, is critical to reducing its impact. Our collaboration with Zydus Lifesciences marks an important milestone in advancing accessible, patient-friendly cancer screening solutions for the people of India. By bringing together innovation, scientific excellence, and a shared commitment to better health outcomes, we can empower individuals to take charge of their health, enable earlier diagnosis, and significantly improve the chances of successful treatment. Together, we are taking another meaningful step toward a future where more lives are saved through early detection and timely intervention." Dr. Sharvil Patel, Managing Director, Zydus Lifesciences Ltd., said, “As India’s leading oncology company, we are reimagining the role of diagnostics in cancer care. We are pleased to partner with Apollo Hospitals and Guardant Health to introduce Shield™ MCD in India, expanding access to an innovative screening technology that complements existing screening pathways. Through focused awareness initiatives, we continue to encourage timely screening and proactive healthcare with our range of companion diagnostics. By expanding access to precision diagnostics, we stand committed to unlocking new possibilities in patient care.” Simranjit Singh, Chief Executive Officer, Guardant Health AMEA added, "We are pleased to bring the Shield Multi-Cancer Detection (MCD) test to India through Apollo Cancer Centres and our longstanding commercial partner Zydus Lifesciences. Earlier detection has the potential to transform cancer outcomes, and Shield MCD represents an important advancement in helping identify cancer-associated signals through a single blood draw. Together, we are expanding access to innovative screening technologies that can support earlier clinical evaluation and help shape the future of cancer care in India." Cancer accounts for nearly nine per cent of total deaths related to non-communicable diseases in India. In 2022, over 1.41 million individuals were diagnosed with cancer, with over 900,000 deaths. Breast cancer is the leading cause of cancer-related mortality among women, while oral cancer is the top cancer among men. However, screening rates in India are low with wide disparity among states. Southern and western regions report the highest cancer screening coverage while northern, central and northeastern regions lag1. *The FDA Breakthrough Device designation referenced eight cancer types—bladder, colorectal, oesophageal, gastric, liver, lung, ovarian, and pancreatic cancer—in individuals aged 45 or older who are at typical average risk for cancer, as defined by the agency at the time of designation. This designation does not imply FDA approval, clearance, or endorsement of the device’s safety or effectiveness. Media Contacts: Zydus Lifesciences Limited Sujatha Rajesh Email: sujatha.rajesh@zyduslife.com Mobile: +91 9974051180 Apollo Hospitals Anjana Parikh Email: anjana_p@apollohospitals.com About Zydus Lifesciences Limited Zydus Lifesciences Ltd., with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 30,000 people worldwide, including 1,500 scientists engaged in R & D, and is driven by its mission to unlock new possibilities in lifesciences through quality healthcare solutions that impact lives. The group aspires to transform lives through pathbreaking discoveries. Over the last decade, Zydus has introduced several innovative, first-in class products in the market for treating unmet healthcare needs with vaccines, therapeutics, biologicals, and New Chemical Entities. For more details visit www.zyduslife.com 1 Vijna, Dubey DK, Mishra P. Determinants of Cancer Screening in India: An Epidemiological Overview. Cureus. 2026;18(1):e102339. Published 2026 Jan 26. doi:10.7759/cureus.102339 About Guardant Health Guardant Health AMEA is a wholly owned subsidiary of Guardant Health, a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening with Shield™ to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the best treatment for patients with advanced cancer. For more information, please visit www.guardanthealthamea.com and follow the company on LinkedIn. About Apollo Hospitals Enterprise Ltd. Apollo revolutionised healthcare when Dr Prathap Reddy opened the first hospital in Chennai in 1983. Today, Apollo is the world’s largest integrated healthcare platform with over 10,900 beds across 78 hospitals, 7,200+ pharmacies, 300+ clinics, 2,500 diagnostic centres. It is one of the world’s leading cardiac centres, having performed over 3,00,000 angioplasties and 2,00,000 surgeries. Apollo continues to invest in research and innovation to bring the most cutting-edge technologies, equipment, and treatment protocols to ensure patients have access to the best care in the world. Apollo’s 1,20,000 family members are dedicated to delivering exceptional care and leaving the world better than we found it. For further details, log onto: www.apollohospitals.com